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J. E n d o c r i n o l . f n v e s t . 1: 47, 1978 
Treatment of patients with prolactinomas 1 
K.v. Werder*, R. Fahlbusch** , R. Landgraf*, C R . Pickardt*, H.K. Rjosk***, and P.C. Scr iba*. 
'Department of Medicine, Innenstadt, **Department of Neurosurgery, and ***lst. Department of Gynecology, 
University of Munich, Fed. Rep. Germany. 
A B S T R A C T . Fiftyone female patients with prolactin producing tumors (PRL 1100 to 88,000/iU/ml) 
and 26 male patients with prolactin producing tumors (PRL 6500 to 400,000 ywU/ml) were studied. 
Only 25% of the females had Visual field defects which were present in 70% of the males. All females 
had amenorrhea but only 35 had galactorrhea. Hypopituitarism was rarely seen in the females but in 
most of the male patients. Twentyfour females and all male patients were operated (trans-
sphenoidal or transfrontal Operation). PRL normalized in only eight females and in none of the 
males. Two patients became pregnant postoperatively, four after postoperative treatment with 
bromocriptine. Bromocriptine induced regulär menses in 4 other patients operated by trans-
sphenoidal route. Eight patients with microadenoma (PRL < 4000 /AJ/ml) were treated with 
bromocriptine alone of whom two became pregnant. The males were also treated with bromocrip-
tine leading to a significant fall of the P R L level accompanied by improvement of libido, sexual 
potency and headache. Two patients received radiation postoperatively, which led to a fall of PRL 
and improvement of Visual fields. Since PRL levels remained low after withdrawal of bromocriptine 
for several months an antiproliferative effect of this drug is suggested. Thus differential therapy of 
P R L producing tumors is possible: In females selective neurosurgery can alone or combined with 
medical therapy normalize P R L secretion and ovarian function. In patients with microadenoma 
bromocriptine alone can be successful. In patients with inoperable large tumors radiation should be 
advocated. Additional bromocriptine therapy may be helfpful to stop tumor growth and alleviate the 
effects of hyperprolactinemia. 
with bromocriptine or a combination of these thera-
peutic regimens (8). 
M A T E R I A L S A N D M E T H O D S 
The patients investigated were referred to us be-
cause of amenorrhea and galactorrhea, because of 
clinical evidence for pituitary insufficiency or be-
cause of Visual field problems. All patients (51 fe-
males - age 21 to 63 years - and 26 males - age 16 
to 42 years) were admitted to the hospital before the 
initiation of surgical or medical therapy in order to 
perform the endocrine evaluation. If patients were 
operated pituitary function tests were repeated 6 
weeks postoperatively. 
Human prolactin was measured by radioimmu-
noassay using the VLS-hPRL for labelling, kindly 
donated by the National Institute of Health. As 
Standard served pooled pregnancy serum, which 
was calibrated with the MRC-Research-Standard 
A-71 /222 (9), kindly supplied by the National Insti-
tute for Medical Research, Holly Hill, London. 20/aU 
of the MRC-Standard A-71 /222 are equivalent to 1 
ng VLS-hPRL from the NIH. As hPRL-antibody 
served a rabbit-antiserum raised against the «little » 
fragment of serum-hPRL, as described previously 
I N T R O D U C T I O N 
Since the radioimmunoassay for human prolactin 
(PRL) has become available (1, 2), a large number of 
patients with elevated prolactin levels has been 
discovered. Particularly in females hyperprolacti-
nemia associated with or without pituitary tumors has 
been shown to be frequently the cause of galactor-
rhea, amenorrhea or anovulatory menstrual cycles 
(3, 4). But also in the male, where galactorrhea is 
usually absent, it could be shown that many pituitary 
tumors formerly thought to be hormonally inactive 
were in fact producing prolactin (3,5). As it has 
turned out the pituitary prolactinoma is the most 
freqüent of all endocrinologically active pituitary 
tumors (6, 7). In the last five years we have been 
following more than 180 patients with hyperprolactin-
emia in our endocrine clinic, who were treated either 
by surgical procedures (6), by conventional radiation, 
1 Presented in part at the V International Congress of Endocrinology, Hamburg 
1976. Abstr. 101. Supported by Deutsche Forschungsgemeinschaft. SFB 51. 
K e y - w o r d s : Prolactin, prolactinomas, bromocriptine 
C o r r e s p o n d e n c e : K. von Werder. Department of Medicine. Innenstadt, University 
of Munich, Fed. Rep. Germany 
Received July 18, 1977; accepted November 2. 1977. 
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K . v . W e r d e r , R. F a h l b u s c h , R. L a n d g r a f , C R . P i c k a r d t , H . K . R j o s k , a n d P.C. S c r i b a 
(10). The bound/free Separation was performed by 
double-antibody procedure. No cross reactivity with 
other pituitary hormones or lactogenic hormones was 
observed in our radioimmunoassay, the lower limit of 
detection was 5 /xU/ml . 
Other hormone determinations: human growth hor-
mone (GH), luteinizing hormone (LH), follicle stimu-
lating hormone (FSH), and thyrotropin (TSH) were 
measured by Standard double-antibody radioimmu-
noassay (3). Serum cortisol was also measured by 
radioimmunoassay, thyroxine by competitive protein 
binding analysis. 
Pituitary function was evaluated with the following 
Stimulation tests: thyrotropin releasing hormone 
(200/xg TRH) for the Stimulation of TSH and PRL; 
gonadotropin releasing hormone (25/xg GnRH) for 
the Stimulation of LH and FSH; insulin hypoglycemia 
(0.15 U /kg body weight) for the Stimulation of cortisol 
a n d G H . 
Anatomical evaluation in order to demonstrate a 
pituitary tumor: All patients had lateral skull X-ray as 
well as sella tomography. Most of the patients had 
computer-tomography (CT) of the skull. In all patients 
Visual fields were examined. 
RESULTS AND DISCUSSION 
Prolactin levels in 51 female patients with amenor-
rhea and/or galactorrhea and pituitary tumors 
ranged from 1100 to 88,000jUU/ml (Fig.1). As it has 
been shown (6), there was a good correlation be-
tween tumor size and the amount of circulating 
prolactin. Thus the prolactin levels in 108 females 
with amenorrhea, galactorrhea and normal sella did 
not exceed 4000/xU/ml (Fig. 1), thougn it cannot be 
excluded that these patients also harbor a pituitary 
microadenoma which has not led to changes of the 
osseous structure of the sella turcica (11). None of 
PRL 
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Fig. 1 - P r o l a c t i n l e v e l s i n 51 f e m a l e s a n d 
2 6 m a l e s w i t h p r o l a c t i n o m a s c o m p a r e d t o 
1 0 8 h y p e r p r o l a c t i n e m i c p a t i e n t s w i t h n o 
r a d i o l o g i c a l e v i d e n c e for a p i t u i t a r y t u m o r . 
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T r e a t m e n t of p r o l a c t i n o m a s 
these patients had any evidence of pituitary insuffi-
ciency documented by pituitary function tests. Only 
25% of the females with pituitary tumors had Visual 
field defects whereas 70% of the male patients had 
suprasellar extension of the tumor documented by 
CT and Visual field defects. Only 11 male patients of 
26 were investigated before the first Operation (Fig. 
1), though all had prolactin levels above 6000/UU/ml 
ranging up to 400,000 (Jüü/m\ in one patient after 
several transfrontal and transsphenoidal pituitary 
Operations, again giving evidence for the good corre-
lation between tumor size and prolactin concentra-
tion. Hypopituitarism demonstrated by insufficient 
responses of pituitary hormones secretion after ap-
propriate Stimulation was rarely seen in the females 
(9%) whereas most of the male patients had lack of 
growth hormone (82%) and gonadotropin (75%) se-
cretion. 
All patients with pituitary tumors and signs of pituitary 
insufficiency and/or evidence for suprasellar exten-
sion were operated by trans-sphenoidal and some-
times trans-cranial route (6). As it has been shown 
(6), it is extremely difficult to eradicate the prolactin 
excess by surgical means if prolactin levels are very 
high (Fig. 2). Thus prolactin levels in 24 females were 
normalised only in 8, of whom 2 became pregnant, 
whereas they remained elevated in the other 16 
patients (Fig. 2). In the male patients with the higher 
prolactin levels no normalization after trans-
sphenoidal hypophysectomy could be observed, 
though there was a significant fall of the basal 
prolactin in each of them (Fig. 2). 
PRL 
Uiu/ml] 
200000 
100000 
50000 
40000 
30000 
20000 
10000 
5 000 
4 000 
3000 
2 000 
1000 
600 
500 
400 
300 
200 
preop. postop. preop. postop. 
Fig. 2 - F a l l of P R L l e v e l s i n 2 4 f e m a l e a n d 10 m a l e p a t i e n t s 
a f t e r O p e r a t i o n . 
PRL 
fiU/ml 
20000 
15 000 
10000 
5 000 
0 L 
visual L U . 
fields anaesthesia 
openmq 
of the sella 
dunng 
adenoma 
resection 
after 
adenoma 
resection 
Visual fields 
PRL normal 
LH 0 
GH 0 
ACTH 0 
TSH 0 
T H E R A P Y : 
I 1 " * 
^ ^ cryohypophysectomy I 
25 mg Hydrocortisone/d (10-5-5-5) 
100 Thyroxine 
50 pg Ethinylestradiol 
2 mg Norethisteroneacetate 
90 in. 
postop. 
Op.-day 25.11. 26.11. 27.11. 29.11. 
-1974-
T 
a i . 5.3. 3.12. 
-1975-
7.4. 
-1976 
Fig. 3 - I n t r a a n d p o s t o p e r a t i v e P R L l e v e l s i n a 2 8 yr o l d p a t i e n t w i t h a l a r g e p r o l a c t i n o m a . T h e l a t e r i s e of P R L a f t e r i n i t i a l 
n o r m a l i z a t i o n S i g n a l s t u m o r r e c u r r e n c e . 
49 
K . v . W e r d e r , R. F a h l b u s c h , R. L a n d g r a f , C R . P i c k a r d t , H . K . R j o s k , a n d P . C . S c r i b a 
Therapy: 
Menstrual 
cycle: 
Trans-sphen 
resection ot 
pituitary tumor 
!—3—+-S-4-—7.5 - —I mg/d 
Amenorrhea -preynancy-
birth of child 
h—7.5mg/d^ | 
hCG* 
second pregr.ancy 
Visual fields: right-temp normal 
defect 
Pituitary G H I I G H 
function: L H | f L H 
T S H J | T S H 
P R L - 7 1 / 2 2 2 
uU/ml 
12 000 j-
3 000 
6000 
2 000 
9 10 
—1974 — 
5 
-1975-
3 
-1976-
Fig. 5 - Pregnancy after 
partial adenomectomy in 
a 32 yr old patient with 
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A typical example for a female patient with galactor-
rhea, amenorrhea, a pituitary tumor and chiasma 
Syndrome is shown in Figure 3. This patient who had 
already impaired anterior pituitary function preoperat-
ively together with suprasellar extension of a large 
prolactin producing adenoma was operated by trans-
sphenoidal route in addition with cryotherapy. Right 
after the Operation the prolactin levels were normal-
ized and Visual field came back to normal whereas 
the patient had now complete anterior pituitary failure 
and required substitutional therapy including es-
trogens because of severe Symptoms due to es-
trogen deficiency. Though in this case a radical 
ablation of the pituitary was intended and performed, 
during recent follow up a gradual increase of the 
prolactin levels was observed suggesting recurrence 
of pituitary tumor growth (12). While revising this 
manuscript no further increase of her serum PRL 
level has been observed (September 14, 1977). 
Since it has been shown that prolactin levels can be 
effectively lowered by dopamine agonists (13,14,15, 
16), we have treated 19 female patients with pituitary 
tumors with bromocriptine, which was well tolerated 
by all of the patients. Bromocriptine in daily dosages 
varying from 3 to 7.5 mg normalized prolactin levels 
in female patients with pituitary tumors, if the post-
operative basal prolactin level did not exceed 10,000 
/ /U /ml (Fig. 4). Four of these patients became preg-
nant after bromocriptine administration and had a 
completely normal pregnancy with healty babies. In 
females with prolactin levels above 10,000 / /U /m l 
even larger doses up to 30 and 40 mg did not lead to 
normalization of prolactin secretion and therefore 
possible cyclic ovarian function. 
A typical example of a patient with a prolactinoma 
with prolactin levels above 12,000/xU/ml, Visual field 
defects and partial pituitary insufficiency docu-
mented by inadequate responses of G H , LH and TSH 
is shown in Figure 5. Since this patient wanted to 
become pregnant, in contrast to the patient shown in 
Figure 3, a selective adenomectomy was intended, 
so that after the Operation pituitary function could 
recover or remain intact. Due to remaining adenoma 
tissue, the basal prolactin levels after Operation 
fluctuated between 4000 and 7000juU/ml. She was 
therefore treated with 7.5 mg bromocriptine per day. 
After the first menstrual period she became pregnant 
and delivered a normal child. After normal breast-
feeding period she was again treated with bromocrip-
tine and became pregnant again, giving birth to a 
second child in February 1977. 
A similar case is shown in Figure 6. After surgical 
resection of the pituitary adenoma without destroying 
residual pituitary function, the still elevated prolactin 
levels could be completely normalized by bromocrip-
tine administration leading to disappearance of gal-
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CYCLE: 
Amenorrhea 
P IMIIIIM 
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Fig. 6 - Normal ovarian function a l l e r partial adenomectomy and subsequeni bromocriptine therapy in a 27 yr old patient with 
galactorrhea, amenorrhea, and pituitary tumor. 
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actorrhea and normal menstrual cycles. After bro-
mocriptine withdrawal, which was given only for a 
Short period, prolactin levels increased again to the 
initial value and galactorrhea and amenorrhea reoc-
curred. 
When prolactin levels were only moderately elevated 
and patients wanted to become pregnant and when 
the pituitary tumor was small without any evidence of 
pituitary dysfunction or suprasellar extension of the 
tumor we have treated these patients with bromo-
criptine alone. Figure 7 shows the course of treat-
ment in a patient with an asymmetrically growing 
pituitary tumor without Visual field defects and no 
evidence for anterior pituitary dysfunction. Prolactin 
levels were 3000 jUU/ml. After therapy with 3 mg 
bromocriptine per day the prolactin levels had nor-
malized and she ovulated regularly. She became 
pregnant and bromocriptine was withdrawn after 
which the prolactin levels rose again during preg-
nancy up to 18,000 f A ) / m \ . She delivered a normal 
child and since her prolactin levels did not fall to 
pretreatment levels and she suffered from heavy 
galactorrhea she was then operated by trans-
sphenoidal route. The Operation was again not radi-
cally performed, because a second pregnancy was 
desired. Therefore her prolactin levels did not drop to 
normal which made bromocriptine therapy necessary 
again leading to regulär menses. 
There is a twofold reason why the indication for 
bromocriptine therapy is not confined to females. The 
first reason for trying to normalize prolactin levels in 
male patients is that also in the male, in contrast to 
former beliefs, hyperprolactinemia exerts biological 
effects (3, 5, 13, 17). It is a frequent clinical Observa-
tion that male patients with high prolactin levels 
suffer from lack of libido in the presence of normal 
testosterone secretion or adequate substitutional 
testosterone therapy (3, 5). Since prolactin has also a 
diabetogenic, i.e. insulin antagonistic effect, the glu-
cose tolerance can deteriorate and diabetes mellitus 
can become evident. 
We have treated 14 male patients who all had 
postoperatively elevated prolactin levels and com-
plained of headaches, depression, particularly loss of 
libido and impotence in the presence of adequate 
testosterone Substitution with bromocriptine (Fig. 8). 
In 7 of the patients prolactin levels were normalized 
by bromocriptine whereas prolactin levels remained 
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C y c l e : Amenorrhea 
- p r e g n a n c y -
Bromocriptine 
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birth of 
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2.5 mg/day 
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G a l a c t o r r h e a : 
PRL-71/222 
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20 000 r 
Lactation 
h 1974 — 1975 •+• 1976 
Fig. 7 - P r e g n a n c y a f t e r b r o m o c r i p t i n e t h e r a p y a l o n e i n a 2 4 yr o l d p a t i e n t w i t h p r o l a c t i n o m a . S i n c e P R L l e v e l s r e m a i n e d e l e v a t e d 
c o m p a r e d t o p r e t r e a t m e n t l e v e l s s h e w a s o p e r a t e d a f t e r d e l i v e r y betöre b r o m o c r i p t i n e w a s s t a r t e d a g a i n . 
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PRL-71/222 
months of treatment tinoma. 
elevated though considerably lowered in the other 7 
patients. The fall of prolactin was in general accom-
panied by clinical improvement and feeling of well 
being. In contrast to the female prolactin levels 
above 10,000 /x l l /m l could be normalized by bro-
mocriptine which may be due to the lack of es-
trogens in the males with their permissive action on 
prolactin secretion (18). This is also demonstrated by 
a male patient who had been operated by trans-
sphenoidal route because of a pituitary prolactinoma 
which was previously thought to be hormonally 
inactive (Fig. 9). Postoperatively he was still having 
prolactin levels above 12,000 / /L i /ml . He suffered 
from lack of libido and sexual impotence though 
there was no evidence for pituitary dysfunction and 
peripheral testosterone levels were in the normal 
ränge. He was put on bromocriptine and after the 
relatively small dose of 3 mg per day prolactin 
secretion normalized and sexual potency as well as 
libido and fertility reverted to normal (Fig. 9). 
The other reason for treating males and females with 
prolactinomas and postoperatively persisting hyper-
prolactinemia with bromocriptine is the now accumu-
lating evidence, that this drug may have an antipro-
liferative effect on lactotropic pituitary tumor growth 
(19, 20). 
Four patients with pituitary tumors and elevated 
prolactin levels were treated for 5 to 20 months with 
bromocriptine in dosages ranging from 5 to 40 mg 
per day (Table 1). Bromocriptine therapy was with-
drawn for a period of 1 - 11 months, after which the 
prolactin levels were still found to be significantly 
lower during at least three different measurements 
on three different days compared to the pretreatment 
levels. This may also suggest an antiproliferative 
effect, though we know little about the spontaneous 
secretory activity of these tumors. Further evidence 
for such an effect may be a male patient with 
excessive hyperprolactinemia after two trans-frontal 
and two trans-sphenoidal Operations (Fig. 10). His 
prolactin levels were extremely elevated - 400,000 
/XU/ml, which is equivalent to 20 f i g of hormone 
protein per ml. This patient who suffers now from 
complete panhypopituitarism due to his invasively 
growing and inoperable prolactin producing tumor, 
complained mainly about headaches, lack of libido 
and sexual potency, and suffered from depression. 
He also had impaired Visual fields. Under chronic 
bromocriptine therapy he feels subjectively better 
and the prolactin levels have fallen from 400,000 to 
less than 5000 jUU/ml. There was no evidence for 
Progression of tumor growth but in contrast the 
perimetry demonstrated improvement of his Visual 
field which may be interpreted as actual shrinking of 
the pituitary tumor (Fig. 10). Alternatively the im-
provement could be due to relief from pressure of the 
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Table 1 - PRL l e v e l s ißUlml) after withdrawal of l o n g - t e r m bromocriptine treatment in 4 female p a t i e n t s with pituitary tumor. 
Patient PRL after Duration of Bromocriptine Time without 
betöre withdrawal treatment bromocriptine 
therapy of therapy (months) (mg/day) (months) 
A.L 49,340 12,982 12 12.5 1 
J.H. 41,910 15,655 5 40 8 
S.L. 16,680 10,678 13 40 11 
G.G. 5,237 3,100 20 5 2 
anterior pathway by tumor and/or edematous 
changes. It could only be proven by pneumencepha-
lography which was not done or Computer tomo-
graphy which is not possible in this patient because 
of the many metal clips from previous Operations. 
That prolactin levels correlate to tumor size has been 
mentioned betöre (6). That prolactin levels correlate 
in individual patients also with tumor growth is docu-
mented by a patient with galactorrhea, amenorrhea 
and a pituitary tumor who was operated by trans-
frontal and trans-sphenoidal route because of impair-
ment of Visual fields (Fig. 11). When this patient was 
first admitted to our hospital after two Operations the 
prolactin levels were still elevated. Düring follow up 
deterioration of Visual fields occurred due to tumor 
growth accompanied by a Sharp rise of basal prol-
actin. She was inoperable because of severe con-
gestive heart failure and was therefore irradiated 
after which prolactin levels feil and a slight improve-
ment of her visual field occurred. She was afterwards 
put on bromocriptine which led to a prompt normali-
sation of her prolactin secretion. 
Bromocriptine has been shown to inhibit growth 
hormone secretion in patients with acromegaly (21, 
22, 23, 24). That bromocriptine can be helpful in 
patients with hypersecretion of GH and PRL is 
demonstrated In the patient shown in Figure 12. This 
acromegalic patient demonstrates quite clearly the 
Problems we sometimes face in managing patients 
with endocrine active pituitary tumors. She was first 
operated in 1969 by trans-frontal Operation in an 
outside Institution. Preoperative growth hormone and 
prolactin levels were not known. The indication for 
Operation was the clinical picture of acromegaly. 
Because of suprasellar extension of the pituitary 
tumor leading to Visual field disturbances she was 
operated agatn by trans-frontal approach which did 
not lower her growth hormone levels at all, though in 
1974 when she appeared at a follow up her growth 
hormone levels were 20 ng/ml and her prolactin 
Hauet Transcranial pituitary Operation 1963 and 
trans-sphenoidal resection of the adenoma 1973 
Visual ftdds: |lmpoirment since19521 (5)(G; -deterioration -
Pituitary Function Amenorrhea 
and galac-
torrhea 
since 1946 
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2?000r 
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Fig. 11 - Correlation of 
p r o l a c t i n levels and p i t u i -
tary tumor growth as 
e v i d e n c e d by increasing 
visual field defects in a 56 
yr old female. 
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levels were 10 ,000 / iU /m l , demonstrating that she 
had hypersecretion of both G H and PRL. Because of 
rapid deterioration of the Visual function of her left 
eye, she came again tp our hpspital and she was 
operated a third time, this time by trans-sphenoidal 
route. Again there was no significant effect on growth 
hormone and prolactin levels which were still very 
high. By Computer tomography it could be demon-
strated that she had para and suprasellar tumor 
growth leading to complete blindness of her left eye. 
We put her therefore on bromocriptine therapy which 
effectively lowered growth hormone and even more 
effectively prolactin levels. We thought this to be 
particularly important since she had in the meantime 
developed breast Cancer which had to be operated. 
The connection between the occurrence of breast 
Cancer and hypersecretion of two lactotropic hor-
mones is still object of speculation (25). In this case 
we think that in addition to bromocriptine therapy 
radiation of her tumor will be necessary after rec-
overing from mastectomy. 
That bromocriptine can inhibit two hormones sec -
reted by pituitary tumor has also been shown in a 
case recently reported by Horn et al. (26), where 
bromocriptine led to lowering of TSH and prolactin in 
a TSH and prolactin producing pituitary tumor. 
GONCLUSIONS 
From the observations of the 51 female and 26 male 
f OPERATION FOR BREAST CANCER 
>5+7.5*10+125H5-«-20H—30—h-40—«mg/day 
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Fig. 12 - Effect of 
multiple surgery a n d 
bromocriptine on PRL 
an GH levels in a 40 yr 
old patient with acro-
megaly and hyperpro-
lactinemia. 
patients with pituitary tumors we can make the 
following conclusions: 
1) Hyperprolactinemia associated with pituitary tu-
mors can be treated surgically, medically and with 
radiotherapy. 
2) All patients having Visual field defects or signs of 
impairment of pituitary function should be operated. If 
Operation is impossible pituitary radiation can be an 
alternative. If prolactin does not normalize after 
Operation or radiation, particularly when these pa-
tients suffer from depression, lack of libido or impo-
tence despite adequate testosterone levels, bromo-
criptine therapy is indicated. 
3) In females with prolactin levels above 5000/ /U/ml 
who want to become pregnant, a gentle neurosur-
gical procedure should induce normalization or low-
ering of prolactin secretion without disturbing gonad-
otropic function that postoperative bromocriptine 
therapy can lead to normal ovulatory cycles. 
4) In patients with small pituitary tumors and hyper-
prolactinemia without any evidence of pituitary insuf-
ficiency or visual field defects bromocriptine alone is 
indicated. If pregnancy occurs these patients have to 
be monitored during pregnancy by measuring prol-
actin levels and visual fields in monthly intervals 
since the enhanced estrogen production may acti-
vate pituitary tumor growth. Radiographic control of 
the sella turcica with appropriate precautions is 
advisable one month before term. 
5) Patients with endocrine active pituitary .adenomas 
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secreting two different hormones seem to be respon-
sive to bromocriptine therapy leading to the abolition 
of both hormone excesses. 
6) There is some evidence that bromocriptine exerts 
an antiproliferative effect on pituitary tumor growth, 
which justifies postoperative bromocriptine adminis-
tration. If consequent postoperative therapy can 
preverrt recurrence of pituitary tumor growth in every 
patient has to be established in the future. 
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